Background
Methods
Design, setting, and study population
Data sources
Variables
Chronic diseases and multimorbidity
Death and drop out
Drugs and polypharmacy
Kidney function
Liver function
Other variables
Statistical analysis
Medication use in multimorbidity patterns
Results
Variables | Cluster 1 - Non-Specific | Cluster 2 - Eye Impairment and Mental | Cluster 3 - Minority Metabolic Autoimmune-Inflammatory | Cluster 4 - Cardio-Circulatory and Renal | Cluster 5 - Cardio-Circulatory, Mental, Respiratory and Genitourinary | Cluster 6 - Neurological, Digestive and Circulatory | Cluster 7 - Respiratory and Ear | Cluster 8 - Digestive | Cluster 9 - Neurological, Musculoskeletal and minor | Cluster 10 - Multisystem Pattern | Overall (patients alive) |
---|---|---|---|---|---|---|---|---|---|---|---|
N2012=384787 (42.0%) - N2016=258700 (34.8%) | N2012=177087 (19.3%) - N2016=155008 (20.8%) | N2012=72190 (7.9%) - N2016=73237 (9.8%) | N2012=60192 (6.6%) - N2016=46244 (6.2%) | N2012=54324 (5.9%) - N2016=45463 (6.1%) | N2012=42422 (4.6%) - N2016=41120 (5.5%) | N2012=41644 (4.5%) - N2016=38961 (5.2%) | N2012=35692 (3.9%) - N2016=31744 (4.3%) | N2012=33283 (3.6%) - N2016=36522 (4.9%) | N2012=14998 (1.6%) - N2016=16828 (2.3%) | N2012=916619 - N2016= 743827 | |
Sex: | |||||||||||
Female | 201958 (52.5%) - 137931 (53.3%) | 130572 (73.7%) - 113574 (73.3%) | 31395 (43.5%) - 31490 (43.0%) | 42638 (70.8%) - 32786 (70.9%) | 3618 (6.7%) - 2902 (6.4%) | 23577 (55.6%) - 22601 (55.0%) | 31143 (74.8%) - 28838 (74.0%) | 19915 (55.8%) - 17846 (56.2%) | 30830 (92.6%) - 33718 (92.3%) | 13485 (89.9%) - 15005 (89.2%) | 529131 (57.8%) - 436691 (58.7%) |
Male | 182829 (47.5%) - 120769 (46.7%) | 46515 (26.3%) - 41434 (26.7%) | 40795 (56.5%) - 41747 (57.0%) | 17554 (29.2%) - 13458 (29.1%) | 50706 (93.3%) - 42561 (93.6%) | 18845 (44.4%) - 18519 (45.0%) | 10501 (25.2%) - 10123 (26.0%) | 15777 (44.2%) - 13898 (43.8%) | 2453 (7.4%) - 2804 (7.7%) | 1513 (10.1%) - 1823 (10.8%) | 387488 (42.2%) - 307136 (41.3%) |
Patients with Multimorbidity: | 323153 (84.0%) - 238466 (92.2%) | 176734 (99.8%) - 154922 (99.9%) | 71562 (99.1%) - 73039 (99.7%) | 60192 (100.0%) - 46243 (100.0%) | 54318 (100.0%) - 45463 (100.0%) | 42126 (99.3%) - 41020 (99.8%) | 41413 (99.4%) - 38885 (99.8%) | 35306 (98.9%) - 31628 (99.6%) | 33283 (100.0%) - 36522 (100.0%) | 14998 (100.0%) - 16828 (100.0%) | 853085 (93.1%) - 723016 (97.2%) |
Patients with Polypharmacy: | 122956 (32.0%) - 84206 (32.5%) | 110504 (62.4%) - 99185 (64.0%) | 43115 (59.7%) - 44500 (60.8%) | 51759 (86.0%) - 40528 (87.6%) | 43829 (80.7%) - 38159 (83.9%) | 30644 (72.2%) - 29788 (72.4%) | 29416 (70.6%) - 28254 (72.5%) | 20336 (57.0%) - 18717 (59.0%) | 22739 (68.3%) - 25338 (69.4%) | 12204 (81.4%) - 13710 (81.5%) | 487502 (53.2%) - 422385 (56.8%) |
Age (Mean): | 74.8 - 73.3 | 74.2 - 73.5 | 75.9 - 74.5 | 80.6 - 78.3 | 76.7 - 75.0 | 78.7 - 76.3 | 75.3 - 74.0 | 74.8 - 73.6 | 72.8 - 72.5 | 76.9 - 75.8 | 75.5 - 74.1 |
Age (n,%): | |||||||||||
[65,70) | 121226 (31.5%) - 96106 (37.1%) | 55687 (31.4%) - 52749 (34.0%) | 17825 (24.7%) - 21292 (29.1%) | 4711 (7.8%) - 5461 (11.8%) | 10906 (20.1%) - 11395 (25.1%) | 5578 (13.1%) - 7904 (19.2%) | 10981 (26.4%) - 12061 (31.0%) | 10135 (28.4%) - 10472 (33.0%) | 12210 (36.7%) - 13773 (37.7%) | 2919 (19.5%) - 3788 (22.5%) | 252178 (27.5%) - 235001 (31.6%) |
[70,80) | 162009 (42.1%) - 113532 (43.9%) | 81567 (46.1%) - 72827 (47.0%) | 31466 (43.6%) - 34163 (46.6%) | 20490 (34.0%) - 20320 (43.9%) | 24074 (44.3%) - 22198 (48.8%) | 16968 (40.0%) - 19730 (48.0%) | 19002 (45.6%) - 18753 (48.1%) | 16359 (45.8%) - 15101 (47.6%) | 16152 (48.5%) - 17933 (49.1%) | 6499 (43.3%) - 7863 (46.7%) | 394586 (43.1%) - 342420 (46%) |
[80,90) | 86495 (22.5%) - 44749 (17.3%) | 36744 (20.7%) - 27946 (18.0%) | 20059 (27.8%) - 16495 (22.5%) | 29143 (48.4%) - 18693 (40.4%) | 17052 (31.4%) - 11113 (24.4%) | 16937 (39.9%) - 12481 (30.4%) | 10335 (24.8%) - 7616 (19.5%) | 8316 (23.3%) - 5851 (18.4%) | 4747 (14.3%) - 4682 (12.8%) | 4916 (32.8%) - 4798 (28.5%) | 234744 (25.6%) - 154424 (20.8%) |
[90,99] | 15057 (3.9%) - 4313 (1.7%) | 3089 (1.7%) - 1486 (1.0%) | 2840 (3.9%) - 1287 (1.8%) | 5848 (9.7%) - 1770 (3.8%) | 2292 (4.2%) - 757 (1.7%) | 2939 (6.9%) - 1005 (2.4%) | 1326 (3.2%) - 531 (1.4%) | 882 (2.5%) - 320 (1.0%) | 174 (0.5%) - 134 (0.4%) | 664 (4.4%) - 379 (2.3%) | 35111 (3.8%) - 11982 (1.6%) |
MEDEA: | |||||||||||
R | 82025 (22.7%) - 54244 (21.6%) | 33553 (20.0%) - 29758 (19.8%) | 15314 (22.7%) - 15667 (22.0%) | 12276 (23.5%) - 9279 (20.7%) | 9282 (19.1%) - 7490 (17.1%) | 8888 (23.7%) - 8089 (20.4%) | 7512 (19.4%) - 7006 (18.6%) | 6396 (19.8%) - 5650 (18.4%) | 4888 (15.4%) - 5456 (15.4%) | 2115 (15.3%) - 2350 (14.5%) | 182249 (21.4%) - 144989 (20.1%) |
U1 | 67060 (18.6%) - 47089 (18.8%) | 26625 (15.9%) - 23782 (15.8%) | 10987 (16.3%) - 11839 (16.6%) | 8247 (15.8%) - 7255 (16.2%) | 7144 (14.7%) - 6673 (15.2%) | 6691 (17.8%) - 7247 (18.3%) | 5657 (14.6%) - 5535 (14.7%) | 5534 (17.1%) - 5400 (17.6%) | 4306 (13.5%) - 4983 (14.1%) | 2540 (18.4%) - 2975 (18.3%) | 144791 (17.0%) - 122778 (17.0%) |
U2 | 58542 (16.2%) - 41383 (16.5%) | 27027 (16.1%) - 24586 (16.3%) | 10976 (16.3%) - 11809 (16.6%) | 8048 (15.4%) - 7160 (16.0%) | 7442 (15.3%) - 7043 (16.0%) | 5862 (15.6%) - 6555 (16.6%) | 6062 (15.6%) - 5999 (15.9%) | 5202 (16.1%) - 5056 (16.4%) | 4964 (15.6%) - 5641 (15.9%) | 2306 (16.7%) - 2806 (17.3%) | 136431 (16.0%) - 118038 (16.4%) |
U3 | 57967 (16.0%) - 40622 (16.2%) | 27628 (16.5%) - 25111 (16.7%) | 10665 (15.8%) - 11607 (16.3%) | 8076 (15.5%) - 7179 (16.0%) | 8077 (16.6%) - 7486 (17.1%) | 6116 (16.3%) - 6568 (16.6%) | 6409 (16.5%) - 6301 (16.7%) | 5192 (16.1%) - 5090 (16.6%) | 5745 (18.1%) - 6362 (18.0%) | 2347 (17.0%) - 2796 (17.2%) | 138222 (16.2%) - 119122 (16.5%) |
U4 | 52828 (14.6%) - 37452 (14.9%) | 27931 (16.6%) - 25006 (16.6%) | 10526 (15.6%) - 10980 (15.4%) | 7832 (15.0%) - 6990 (15.6%) | 8361 (17.2%) - 7777 (17.7%) | 5329 (14.2%) - 5952 (15.0%) | 6730 (17.4%) - 6644 (17.6%) | 5194 (16.1%) - 4974 (16.2%) | 6003 (18.9%) - 6580 (18.6%) | 2254 (16.3%) - 2724 (16.8%) | 132988 (15.6%) - 115079 (16.0%) |
U5 | 42956 (11.9%) - 30178 (12.0%) | 25050 (14.9%) - 22140 (14.7%) | 8855 (13.2%) - 9253 (13.0%) | 7775 (14.9%) - 6880 (15.4%) | 8236 (17.0%) - 7432 (16.9%) | 4686 (12.5%) - 5164 (13.0%) | 6378 (16.5%) - 6282 (16.6%) | 4805 (14.9%) - 4572 (14.9%) | 5894 (18.5%) - 6379 (18.0%) | 2248 (16.3%) - 2593 (16.0%) | 116883 (13.7%) - 100873 (14.0%) |
N. Chronic diseases, median [IQR]: | 4.0 [2.0;5.0] - 5.0 [3.0;6.0] | 6.0 [5.0;8.0] - 8.0 [6.0;9.0] | 7.0 [5.0;8.0] - 8.0 [6.0;10.0] | 9.0 [7.0;11.0] - 10.0 [8.0;12.0] | 8.0 [7.0;10.0] - 10.0 [8.0;12.0] | 7.0 [5.0;9.0] - 9.0 [6.0;11.0] | 7.0 [5.0;9.0] - 9.0 [7.0;11.0] | 7.0 [5.0;9.0] - 8.0 [6.0;11.0] | 9.0 [7.0;10.0] - 10.0 [9.0;12.0] | 11.0 [10.0;13.0] - 13.0 [11.0;15.0] | 6.0 [4.0;8.0] - 7.0 [5.0;10.0] |
N. Chronic diseases (n,%): | |||||||||||
0 | 25380 (6.6%) - 6584 (2.5%) | 0 (0.0%) - 0 (0.0%) | 0 (0.0%) - 0 (0.0%) | 0 (0.0%) - 0 (0.0%) | 0 (0.0%) - 0 (0.0%) | 0 (0.0%) - 0 (0.0%) | 0 (0.0%) - 0 (0.0%) | 0 (0.0%) - 0 (0.0%) | 0 (0.0%) - 0 (0.0%) | 0 (0.0%) - 0 (0.0%) | 25380 (2.8%) - 6584 (0.9%) |
1 | 36254 (9.4%) - 13650 (5.3%) | 353 (0.2%) - 86 (0.1%) | 628 (0.9%) - 198 (0.3%) | 0 (0.0%) - 1 (0.0%) | 6 (0.0%) - 0 (0.0%) | 296 (0.7%) - 100 (0.2%) | 231 (0.6%) - 76 (0.2%) | 386 (1.1%) - 116 (0.4%) | 0 (0.0%) - 0 (0.0%) | 0 (0.0%) - 0 (0.0%) | 38154 (4.2%) - 14227 (1.9%) |
[ 2, 5) | 201282 (52.3%) - 108605 (42.0%) | 30742 (17.4%) - 11516 (7.4%) | 13785 (19.1%) - 7640 (10.4%) | 1809 (3.0%) - 549 (1.2%) | 1974 (3.6%) - 506 (1.1%) | 6032 (14.2%) - 3276 (8.0%) | 5751 (13.8%) - 2428 (6.2%) | 6751 (18.9%) - 3105 (9.8%) | 698 (2.1%) - 173 (0.5%) | 12 (0.1%) - 1 (0.0%) | 268836 (29.3%) - 137799 (18.5%) |
[ 5,10) | 120673 (31.4%) - 126309 (48.8%) | 132238 (74.7%) - 111530 (72.0%) | 47338 (65.6%) - 44773 (61.1%) | 32584 (54.1%) - 17095 (37.0%) | 34571 (63.6%) - 19151 (42.1%) | 25615 (60.4%) - 21911 (53.3%) | 25450 (61.1%) - 20204 (51.9%) | 21261 (59.6%) - 17305 (54.5%) | 20365 (61.2%) - 13811 (37.8%) | 3614 (24.1%) - 1583 (9.4%) | 463709 (50.6%) - 393672 (52.9%) |
≥10 | 1198 (0.3%) - 3552 (1.4%) | 13754 (7.8%) - 31876 (20.6%) | 10439 (14.5%) - 20626 (28.2%) | 25799 (42.9%) - 28599 (61.8%) | 17773 (32.7%) - 25806 (56.8%) | 10479 (24.7%) - 15833 (38.5%) | 10212 (24.5%) - 16253 (41.7%) | 7294 (20.4%) - 11218 (35.3%) | 12220 (36.7%) - 22538 (61.7%) | 11372 (75.8%) - 15244 (90.6%) | 120540 (13.2%) - 191545 (25.8%) |
N. of drugs, median [IQR]: | 3.0 [1.0;5.0] - 3.0 [1.0;5.0] | 6.0 [3.0;8.0] - 6.0 [4.0;8.0] | 5.0 [3.0;8.0] - 5.0 [3.0;8.0] | 8.0 [6.0;11.0] - 8.0 [6.0;11.0] | 8.0 [5.0;10.0] - 6.0 [8.0;10.0] | 7.0 [4.0;10.0] - 7.0 [4.0;9.0] | 7.0 [4.0;10.0] - 7.0 [4.0;10.0] | 5.0 [3.0;8.0] - 5.0 [3.0;8.0] | 6.0 [4.0;9.0] - 6.0 [4.0;9.0] | 8.0 [5.0;11.0] - 8.0 [5.0;10.0] | 5.0 [2.0;8.0] - 5.0 [3.0;8.0] |
N. of drugs (n,%): | |||||||||||
0 | 82698 (21.5%) - 41989 (16.2%) | 9688 (5.5%) - 5355 (3.5%) | 5408 (7.5%) - 3759 (5.1%) | 2540 (4.2%) - 761 (1.6%) | 2186 (4.0%) - 800 (1.8%) | 2815 (6.6%) - 1463 (3.6%) | 2366 (5.7%) - 1293 (3.3%) | 3597 (10.1%) - 2199 (6.9%) | 1473 (4.4%) - 1068 (2.9%) | 597 (4.0%) - 265 (1.6%) | 113368 (12.4%) - 58952 (7.9%) |
1 | 39683 (10.3%) - 28971 (11.2%) | 6639 (3.7%) - 5728 (3.7%) | 3467 (4.8%) - 3626 (5.0%) | 505 (0.8%) - 353 (0.8%) | 929 (1.7%) - 624 (1.4%) | 1161 (2.7%) - 1257 (3.1%) | 1246 (3.0%) - 1222 (3.1%) | 2083 (5.8%) - 1822 (5.7%) | 1159 (3.5%) - 1305 (3.6%) | 210 (1.4%) - 283 (1.7%) | 57082 (6.2%) - 45191 (6.1%) |
[ 2, 5) | 139450 (36.2%) - 103534 (40.0%) | 50256 (28.4%) - 44740 (28.9%) | 20200 (28.0%) - 21352 (29.2%) | 5388 (9.0%) - 4602 (10.0%) | 7380 (13.6%) - 5880 (12.9%) | 7802 (18.4%) - 8612 (20.9%) | 8616 (20.7%) - 8192 (21.0%) | 9676 (27.1%) - 9006 (28.4%) | 7912 (23.8%) - 8811 (24.1%) | 1987 (13.2%) - 2570 (15.3%) | 258667 (28.2%) - 217299 (29.2%) |
[ 5,10) | 108886 (28.3%) - 76263 (29.5%) | 88542 (50.0%) - 79758 (51.5%) | 32682 (45.3%) - 34143 (46.6%) | 28606 (47.5%) - 23462 (50.7%) | 26833 (49.4%) - 23058 (50.7%) | 19941 (47.0%) - 20083 (48.8%) | 18623 (44.7%) - 18442 (47.3%) | 14879 (41.7%) - 13799 (43.5%) | 16599 (49.9%) - 18510 (50.7%) | 7090 (47.3%) - 8278 (49.2%) | 362681 (39.6%) - 315796 (42.5%) |
≥10 | 14070 (3.7%) - 7943 (3.1%) | 21962 (12.4%) - 19427 (12.5%) | 10433 (14.5%) - 10357 (14.1%) | 23153 (38.5%) - 17066 (36.9%) | 16996 (31.3%) - 15101 (33.2%) | 10703 (25.2%) - 9705 (23.6%) | 10793 (25.9%) - 9812 (25.2%) | 5457 (15.3%) - 4918 (15.5%) | 6140 (18.4%) - 6828 (18.7%) | 5114 (34.1%) - 5432 (32.3%) | 124821 (13.6%) - 106589 (14.3%) |
N. of visits, median [IQR]: | 7.0 [3.0;12.0] - 7.0 [3.0;12.0] | 10.0 [6.0;16.0] - 10.0 [6.0;16.0] | 10.0 [6.0;17.0] - 10.0 [6.0;18.0] | 20.0 [11.0;32.0] - 22.0 [11.0;34.0] | 14.0 [9.0;23.0] - 15.0 [9.0;25.0] | 12.0 [7.0;20.0] - 12.0 [7.0;21.0] | 12.0 [7.0;20.0] - 12.0 [7.0;20.0] | 11.0 [6.0;19.0] - 11.0 [6.0;19.0] | 12.0 [8.0;19.0] - 12.0 [8.0;19.0] | 15.0 [9.0;23.0] - 15.0 [9.0;24.0] | 9.0 [5.0;16.0] - 10.0 [5.0;17.0] |
N. of visits (n,%): | |||||||||||
0 | 36975 (9.6%) - 17397 (6.7%) | 3722 (2.1%) - 2380 (1.5%) | 1839 (2.5%) - 1335 (1.8%) | 863 (1.4%) - 390 (0.8%) | 763 (1.4%) - 395 (0.9%) | 1147 (2.7%) - 780 (1.9%) | 779 (1.9%) - 544 (1.4%) | 1205 (3.4%) - 749 (2.4%) | 390 (1.2%) - 311 (0.9%) | 262 (1.7%) - 131 (0.8%) | 47945 (5.2%) - 24412 (3.3%) |
1 | 23812 (6.2%) - 14629 (5.7%) | 3649 (2.1%) - 3624 (2.3%) | 1830 (2.5%) - 1922 (2.6%) | 649 (1.1%) - 498 (1.1%) | 629 (1.2%) - 568 (1.2%) | 1051 (2.5%) - 1013 (2.5%) | 749 (1.8%) - 672 (1.7%) | 1043 (2.9%) - 866 (2.7%) | 315 (0.9%) - 417 (1.1%) | 157 (1.0%) - 187 (1.1%) | 33884 (3.7%) - 24396 (3.3%) |
[ 2, 5) | 77936 (20.3%) - 54464 (21.1%) | 20693 (11.7%) - 18928 (12.2%) | 9076 (12.6%) - 9669 (13.2%) | 3064 (5.1%) - 2534 (5.5%) | 3739 (6.9%) - 3050 (6.7%) | 4606 (10.9%) - 4510 (11.0%) | 3793 (9.1%) - 3558 (9.1%) | 4310 (12.1%) - 3938 (12.4%) | 2386 (7.2%) - 2866 (7.8%) | 836 (5.6%) - 1104 (6.6%) | 130439 (14.2%) - 104621 (14.1%) |
[ 5, 10) | 117379 (30.5%) - 82678 (32.0%) | 52731 (29.8%) - 46906 (30.3%) | 20119 (27.9%) - 20721 (28.3%) | 8287 (13.8%) - 5948 (12.9%) | 10988 (20.2%) - 9136 (20.1%) | 9698 (22.9%) - 9891 (24.1%) | 10028 (24.1%) - 9391 (24.1%) | 9029 (25.3%) - 8329 (26.2%) | 8278 (24.9%) - 8991 (24.6%) | 2812 (18.7%) - 3234 (19.2%) | 249349 (27.2%) - 205225 (27.6%) |
≥10 | 128685 (33.4%) - 89532 (34.6%) | 96292 (54.4%) - 83170 (53.7%) | 39326 (54.5%) - 39590 (54.1%) | 47329 (78.6%) - 36874 (79.7%) | 38205 (70.3%) - 32314 (71.1%) | 25920 (61.1%) - 24926 (60.6%) | 26295 (63.1%) - 24796 (63.6%) | 20105 (56.3%) - 17862 (56.3%) | 21914 (65.8%) - 23937 (65.5%) | 10931 (72.9%) - 12172 (72.3%) | 455002 (49.7%) - 385173 (51.8%) |
Characteristics of medication use in relation to multimorbidity patterns
-
Cluster2 (C2)-Eye Impairment and Mental: The most used drugs at baseline were ophthalmologic beta blockers. It should be noted that more than half of the general population with glaucoma and under treatment with ophthalmic beta blockers are included in this cluster (Exclusivity 50.59 and 48.75% at baseline, respectively).
-
Cluster3 (C3)-Minority Metabolic Autoimmune-Inflammatory: At baseline, the most overrepresented drugs were glucocorticoids, uric acid lowering agents, and Vitamin D and analogues.
-
Cluster4 (C4)-Cardio-Circulatory and Renal: At baseline, people included in this pattern had 17 different drug groups overrepresented, mainly to treat ischemic cardiovascular disease, heart failure, valvular heart disease, cardiac arrhythmias, diabetes, kidney failure and anaemia (Fig. 2).
-
Cluster5 (C5)-Cardio-Circulatory, Mental, Respiratory and Genitourinary: At baseline, people included in this pattern had 20 different drug groups overrepresented: peripheral vasodilators, bronchodilators, drugs for ischemic cardiomyopathy, heart failure, prostate diseases and diabetes.
-
Cluster6 (C6)-Neurological, Digestive and Circulatory: Overrepresentation in this cluster is mostly constituted by patients with Parkinson’s disease and corresponding treatment, mainly dopamine, dopamine derivatives and other medicines used in neurological disorders. These diseases and related medications are practically exclusive to this cluster (more than 90.0% at the beginning of the study).
-
Cluster7 (C7)-Respiratory and Ear: Drugs included in this cluster were glucocorticoids, adrenergics in combination with corticosteroids or other drugs excluding anticholinergics, selective beta-2-adrenoreceptor agonists, anticholinergics, corticosteroids, and antihistamines for systemic use.
-
Cluster8 (C8)-Digestive: The most prescribed medication corresponds to drugs used for the treatment of chronic liver diseases.
-
Cluster9 (C9)-Neurological, Musculoskeletal and Minor: In this group the most overrepresented drugs are anti-inflammatory and analgesics, in agreement with the MP.
-
Cluster10 (C10)-Multisystem: The least common pattern, it has multiple overrepresented disorders from different systems, and the corresponding medications used to treat these disorders.